Abstract:e20526 Background: Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment of metastatic and advanced non-small cell lung cancer (NSCLC). However, its application in neoadjuvant scenario has not been well established. Here, we conducted a retrospective study to evaluate the efficacy and safety of neoadjuvant chemo-immunotherapy for patients with potentially resectable NSCLC. Methods: We retrospectively reviewed clinical records of patients with potentially resectable NSCLC (stage IIIA-IIIB) with non-driver gene mutation. The patients underwent neoadjuvant chemo-immunotherapy between March 2019 and October 2020. The outcomes included R0 resection rate, pathologic complete responses (pCR), major pathologic responses (MPR) and safety. The data of whole exome sequencing (WES) and RNA-sequencing (RNA-seq) from tumor samples respectively collected at baseline and at surgery after neoadjuvant therapy were also evaluated. Results: Out of a total of 30 stage III NSCLC patients (29 males and 1 female) at a median age of 56.5 years (range: 46-74), 22 patients (73.3%) had squamous cell carcinoma. Patients received toripalimab/pembrolizumab and platinum-doublet chemotherapy for 2 cycles before surgery. The median duration from final treatment to surgery was 31 days (range: 22-82). One patient refused surgery, and 6 patients did not meet the surgical standards. 23 patients (76.7%) downstaged and reached the surgical standards after neoadjuvant therapy. Out of 23 patients with R0 surgical resection, 16 patients (69.6%) achieved MPR, including 7 patients (30.4%) achieved pCR. The median follow-up duration was 13 months (range: 2-21). As of Jan 20, 2021, no patient had relapsed or died. All grade and grade 3-4 treatment-related adverse events (TRAEs) were reported in 43.3% and 10% of patients, respectively. The most common grade 1-2 TRAEs were transaminase increased (13.3%) and hypothyroidism (16.7%). One patient delayed surgical treatment due to grade 4 transaminase increased. Baseline expression of type-I HLA molecule was lower in MPR/pCR group than that in non-MPR group (HLA-F: p = 0.052). After neoadjuvant therapy, the expression of HLA-F in MPR/pCR patients was significantly increased (p = 0.0047) while the expression of HLA-B in non-MPR patients was decreased (p = 0.032) compared to that of the baseline, suggesting that neoadjuvant therapy may potentially facilitate specific antigen presentation in the tumor tissues of patients with MPR/pCR. Conclusions: Neoadjuvant chemo-immunotherapy for potentially resectable NSCLC is a tolerable treatment with an improved surgical resection rate, MPR and pCR. Based on our findings, a prospective, single arm, phase II study of neoadjuvant toripalimab combined with platinum-doublet chemotherapy is currently being conducted (NCT04144608). Clinical trial information: NCT04324151.

Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis

Treatment Patterns and Clinical Outcomes of Patients with Resectable Non–small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy: A Large-Scale, Multicenter, Real-World Study (Neor-World)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer

Association of Pathological Response with Long-Term Survival Outcomes after Neoadjuvant Immunotherapy: A Meta-Analysis

Does Major Pathological Response after Neoadjuvant Immunotherapy in Resectable Nonsmall-Cell Lung Cancers Predict Prognosis? A Systematic Review and Meta-Analysis

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Efficacy and Safety of Pembrolizumab Plus Chemotherapy and Sequential Surgical Resection in Initial Unresectable Stage IIIB NSCLC.

Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

Neoadjuvant Immunotherapy or Chemoimmunotherapy in Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer

Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis

Neoadjuvant Chemoimmunotherapy for NSCLC

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

Neoadjuvant immunotherapy for advanced, resectable non‐small cell lung cancer: A systematic review and meta‐analysis

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer.

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study

Short-term Outcome of Neoadjuvant Immunotherapy and Chemotherapy in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis